دورية أكاديمية
Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide.
| العنوان: | Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide. |
|---|---|
| المؤلفون: | Carter T; Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, United States., Valenzuela RK; Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, United States., Yerukala Sathipati S; Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, United States., Medina-Flores R; Department of Pathology (Neuropathology), Marshfield Clinic, Marshfield, WI, United States. |
| المصدر: | Frontiers in genetics [Front Genet] 2023 Dec 18; Vol. 14, pp. 1320789. Date of Electronic Publication: 2023 Dec 18 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101560621 Publication Model: eCollection Cited Medium: Print ISSN: 1664-8021 (Print) Linking ISSN: 16648021 NLM ISO Abbreviation: Front Genet Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation. |
| مستخلص: | Background: Glioblastoma (GBM) prognosis remains extremely poor despite standard treatment that includes temozolomide (TMZ) chemotherapy. To discover new GBM drug targets and biomarkers, genes signatures associated with survival and TMZ resistance in GBM patients treated with TMZ were identified. Methods: GBM cases in The Cancer Genome Atlas who received TMZ ( n = 221) were stratified into subgroups that differed by median overall survival (mOS) using network-based stratification to cluster patients whose somatic mutations affected genes in similar modules of a gene interaction network. Gene signatures formed from differentially mutated genes in the subgroup with the longest mOS were used to confirm their association with survival and TMZ resistance in independent datasets. Somatic mutations in these genes also were assessed for an association with OS in an independent group of 37 GBM cases. Results: Among the four subgroups identified, subgroup four ( n = 71 subjects) exhibited the longest mOS at 18.3 months (95% confidence interval: 16.2, 34.1; p = 0.0324). Subsets of the 86 genes that were differentially mutated in this subgroup formed 20-gene and 8-gene signatures that predicted OS in two independent datasets (Spearman's rho of 0.64 and 0.58 between actual and predicted OS; p < 0.001). Patients with mutations in five of the 86 genes had longer OS in a small, independent sample of 37 GBM cases, but this association did not reach statistical significance ( p = 0.07). Thirty-one of the 86 genes formed signatures that distinguished TMZ-resistant GBM samples from controls in three independent datasets (area under the curve ≥ 0.75). The prognostic and TMZ-resistance signatures had eight genes in common ( ANG , BACH1 , CDKN2C , HMGA1 , IFI16 , PADI4 , SDF4 , and TP53INP1 ). The latter three genes have not been associated with GBM previously. Conclusion: PADI4 , SDF4 , and TP53INP1 are novel therapy and biomarker candidates for GBM. Further investigation of their oncologic functions may provide new insight into GBM treatment resistance mechanisms. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Carter, Valenzuela, Yerukala Sathipati and Medina-Flores.) |
| References: | Annu Rev Med. 2022 Jan 27;73:279-292. (PMID: 34665646) Front Oncol. 2014 Apr 14;4:64. (PMID: 24782981) Mol Cancer Ther. 2013 Feb;12(2):162-72. (PMID: 23243059) Cell Death Differ. 2012 Sep;19(9):1525-35. (PMID: 22421968) BMC Gastroenterol. 2022 Jan 19;22(1):25. (PMID: 35045833) Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168) Nat Methods. 2013 Nov;10(11):1108-15. (PMID: 24037242) Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. (PMID: 30371878) PLoS One. 2011 Apr 05;6(4):e18588. (PMID: 21483692) J Biol Chem. 2006 Mar 31;281(13):8600-6. (PMID: 16443602) Neuro Oncol. 2018 Apr 9;20(5):666-673. (PMID: 29126203) Biomed Res Int. 2018 Dec 31;2018:6204676. (PMID: 30687753) Mol Oncol. 2023 Mar;17(3):518-533. (PMID: 36606322) Clin Cancer Res. 2023 Jan 17;29(2):488-500. (PMID: 36239995) Cancer Discov. 2023 Jul 7;13(7):1696-1719. (PMID: 37140445) J Neurooncol. 2023 Aug;164(1):11-29. (PMID: 37458855) Acta Pharmacol Sin. 2023 Mar;44(3):670-679. (PMID: 36100765) Cancer Drug Resist. 2021;4:17-43. (PMID: 34337348) Nat Biotechnol. 2013 Mar;31(3):213-9. (PMID: 23396013) Neuro Oncol. 2012 Jul;14(7):870-81. (PMID: 22711607) Nat Rev Neurol. 2014 Jul;10(7):372-85. (PMID: 24912512) Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795) Genome Res. 2010 Sep;20(9):1297-303. (PMID: 20644199) Cancer Treat Rev. 1997 Jan;23(1):35-61. (PMID: 9189180) Cell. 1997 Nov 14;91(4):479-89. (PMID: 9390557) Proteomics Clin Appl. 2009 Apr;3(4):433-51. (PMID: 21136970) Nature. 2020 May;581(7809):434-443. (PMID: 32461654) Nat Genet. 2013 Oct;45(10):1141-9. (PMID: 23917401) Mol Med Rep. 2019 Apr;19(4):3087-3094. (PMID: 30816464) N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010) Sci Rep. 2016 Dec 21;6:39743. (PMID: 28000777) J Clin Oncol. 2008 Jun 20;26(18):3015-24. (PMID: 18565887) Expert Opin Ther Targets. 2016 Oct;20(10):1169-79. (PMID: 27486901) Genes Chromosomes Cancer. 2017 Aug;56(8):639-650. (PMID: 28437838) Cancers (Basel). 2021 Jul 17;13(14):. (PMID: 34298797) Cell. 2022 Aug 4;185(16):2899-2917.e31. (PMID: 35914528) Neuro Oncol. 2014 May;16(5):696-706. (PMID: 24335699) Cancer Res. 2009 Nov 15;69(22):8761-9. (PMID: 19843866) Front Immunol. 2020 Oct 15;11:582106. (PMID: 33178210) Int Immunopharmacol. 2022 Feb;103:108451. (PMID: 34923423) Comput Struct Biotechnol J. 2014 Nov 15;13:8-17. (PMID: 25750696) Cancer Res. 2005 Jun 1;65(11):4861-9. (PMID: 15930307) Int J Biol Sci. 2016 Apr 25;12(6):677-87. (PMID: 27194945) Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. (PMID: 36370105) Nucleic Acids Res. 2013 Apr 1;41(6):e67. (PMID: 23303777) Mol Cancer Ther. 2013 Nov;12(11):2529-40. (PMID: 23960094) Nucleic Acids Res. 2021 Jan 8;49(D1):D325-D334. (PMID: 33290552) J Clin Oncol. 2009 Dec 1;27(34):5743-50. (PMID: 19805672) Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142) Mol Cancer. 2009 Oct 14;8:85. (PMID: 19828042) Neuro Oncol. 2020 Aug 17;22(8):1073-1113. (PMID: 32328653) Cancers (Basel). 2022 Apr 29;14(9):. (PMID: 35565362) Cancer Res. 2001 Mar 1;61(5):1957-63. (PMID: 11280752) Acta Neuropathol. 2011 May;121(5):651-61. (PMID: 21287394) BMC Cancer. 2013 Mar 22;13:147. (PMID: 23522185) J Neuropathol Exp Neurol. 2016 Mar;75(3):246-55. (PMID: 26883115) Clin Cancer Res. 2009 Jul 15;15(14):4622-9. (PMID: 19584161) Nat Protoc. 2019 Mar;14(3):703-721. (PMID: 30804569) Anesth Analg. 2018 Sep;127(3):792-798. (PMID: 30015653) Sci Data. 2018 Aug 14;5:180158. (PMID: 30106394) Br J Cancer. 2022 Aug;127(3):422-435. (PMID: 35418212) Bioinformatics. 2018 Aug 15;34(16):2859-2861. (PMID: 29608663) Nat Commun. 2021 Feb 22;12(1):1226. (PMID: 33619257) Cell Rep. 2016 Jun 14;15(11):2500-9. (PMID: 27264189) Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11501-6. (PMID: 20534551) J Biol Chem. 1993 Jul 25;268(21):15878-86. (PMID: 8340413) Semin Immunol. 2020 Feb;47:101393. (PMID: 31932199) Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21. (PMID: 11309499) Nature. 2008 Oct 23;455(7216):1061-8. (PMID: 18772890) Cell Death Differ. 2018 Jan;25(1):114-132. (PMID: 29125603) Anticancer Agents Med Chem. 2014 Jan;14(1):9-17. (PMID: 23387973) Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33. (PMID: 25431634) J Biol Chem. 2003 Sep 26;278(39):37722-9. (PMID: 12851404) Arch Biochem Biophys. 2022 Mar 15;717:109125. (PMID: 35081374) Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426. (PMID: 30407594) Lancet Oncol. 2014 Sep;15(10):1100-8. (PMID: 25163906) Anesth Analg. 2018 May;126(5):1763-1768. (PMID: 29481436) Nat Rev Neurol. 2022 Apr;18(4):221-236. (PMID: 35277681) J Exp Clin Cancer Res. 2022 Nov 16;41(1):323. (PMID: 36380368) Mol Cell Proteomics. 2006 Jan;5(1):157-71. (PMID: 16215274) Oncogene. 2013 Mar 21;32(12):1539-48. (PMID: 22614016) J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676) JCO Clin Cancer Inform. 2020 Apr;4:321-335. (PMID: 32282230) Nat Commun. 2023 Jan 27;14(1):441. (PMID: 36707509) Biochem Biophys Res Commun. 2017 Jan 1;482(1):50-56. (PMID: 27818200) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) J Biol Chem. 2012 Jul 27;287(31):25941-53. (PMID: 22605338) |
| معلومات مُعتمدة: | UL1 TR000427 United States TR NCATS NIH HHS; UL1 TR002373 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: chemotherapy resistance; glioblastoma; oncogene; somatic variant; temozolomide |
| تواريخ الأحداث: | Date Created: 20240123 Latest Revision: 20240411 |
| رمز التحديث: | 20240411 |
| مُعرف محوري في PubMed: | PMC10802164 |
| DOI: | 10.3389/fgene.2023.1320789 |
| PMID: | 38259614 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-8021 |
|---|---|
| DOI: | 10.3389/fgene.2023.1320789 |